ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
103,391.41
-0.71%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Gilead Sciences Inc (GILD) 시세

Gilead Sciences Inc

Gilead Sciences Inc (GILD)

DMG Mori AG
DMG Mori AG
DMG Mori AG
DMG Mori AG
Guild Esports Plc
91.84
0.19
(0.21%)
마감 18 1월 6:00AM
15분 지연
91.84
0.00
(0.00%)
시간외 거래: 9:50AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
91.84
매수가
90.28
매도가
92.10
거래량
6,862,213
91.685 일간 변동폭 92.80
62.07 52주 범위 98.90
market_cap
114.457B
전일 종가
91.65
개장가
92.01
최근 거래 시간
59
@
91.84
마지막 거래 시간
재정 규모
US$ 632,370,248
VWAP
92.1525
평균 볼륨(3m)
6,886,219
발행 주식
1,246,265,857
배당수익률
3.35%
주가수익률
20.20
주당순이익(EPS)
4.55
매출
27.12B
순이익
5.67B

Gilead Sciences Inc 정보

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.gilead.com
본부
Wilmington, Delaware, USA
설립됨
-
Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker GILD. The last closing price for Gilead Sciences was US$91.65. Over the last year, Gilead Sciences shares have traded in a share price range of US$ 62.07 to US$ 98.90.

Gilead Sciences currently has 1,246,265,857 shares in issue. The market capitalisation of Gilead Sciences is US$114.22 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 20.20.

Gilead Sciences (GILD) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

강세

순 프리미엄

906k

Calls / Puts

475.00%

매수 / 매도

109.09%

OTM / ITM

64.29%

Sweeps 비율

0.00%

GILD 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

17 1월 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 1월 2025
Edgar (US Regulatory)

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead...

12 1월 2025
Business Wire

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

11 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 1월 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

04 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 12월 2024
Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

24 12월 2024
Edgar (US Regulatory)

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025...

21 12월 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

20 12월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
11.852.05578397689.9993.0788.57776469591.04285961CS
40.7450.81782754267591.09594.5588.57632921591.64494564CS
122.39492.6775083263489.445198.986.08688621991.64678121CS
2619.5927.114186851272.2598.970.78644280885.50477427CS
526.017.002213678285.8398.962.07696075877.55229216CS
15620.4228.591430971771.4298.957.165712414373.96749728CS
26028.4344.835199495363.4198.956.56840919671.88356654CS

GILD - Frequently Asked Questions (FAQ)

What is the current Gilead Sciences share price?
The current share price of Gilead Sciences is US$ 91.84
How many Gilead Sciences shares are in issue?
Gilead Sciences has 1,246,265,857 shares in issue
What is the market cap of Gilead Sciences?
The market capitalisation of Gilead Sciences is USD 114.22B
What is the 1 year trading range for Gilead Sciences share price?
Gilead Sciences has traded in the range of US$ 62.07 to US$ 98.90 during the past year
What is the PE ratio of Gilead Sciences?
The price to earnings ratio of Gilead Sciences is 20.2
What is the cash to sales ratio of Gilead Sciences?
The cash to sales ratio of Gilead Sciences is 4.22
What is the reporting currency for Gilead Sciences?
Gilead Sciences reports financial results in USD
What is the latest annual turnover for Gilead Sciences?
The latest annual turnover of Gilead Sciences is USD 27.12B
What is the latest annual profit for Gilead Sciences?
The latest annual profit of Gilead Sciences is USD 5.67B
What is the registered address of Gilead Sciences?
The registered address for Gilead Sciences is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Gilead Sciences website address?
The website address for Gilead Sciences is www.gilead.com
Which industry sector does Gilead Sciences operate in?
Gilead Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

GILD Discussion

게시물 보기
jondoeuk jondoeuk 2 월 전
They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/
👍️0
jondoeuk jondoeuk 2 월 전
Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

* https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8
👍️0
fink fink 2 월 전
CEO is talking now.
The stock is selling off on great words.
Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

They should be allowed to make a buck or two.
I want $250 a share please, I've held it way too long.
👍️0
Monksdream Monksdream 2 월 전
GILD, 10Q 11/6
👍️0
Monksdream Monksdream 3 월 전
GILD a new 52 week high
👍️0
Monksdream Monksdream 3 월 전
GILD new 52=week high
👍️0
jondoeuk jondoeuk 3 월 전
Two years later, and here are some of my takeaways...

- They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

- Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is
👍️0
jondoeuk jondoeuk 3 월 전
''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine
👍️0
jondoeuk jondoeuk 3 월 전
https://x.com/JackSha90859576/status/1847728103021281381
👍️0
TechandBio TechandBio 4 월 전
Wants to go higher!

$GILD
👍️0
Monksdream Monksdream 4 월 전
GILD approaching a 52 week high
👍️0
north40000 north40000 4 월 전
Featured on CNBC-TV this morning, 8:40 a.m. time frame.
👍️0
TechandBio TechandBio 6 월 전
NICE!

clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

$GILD
👍️0
TechandBio TechandBio 6 월 전
Adding shares and calls under $80..00

HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



$GILD
$GILD
👍️0
midastouch017 midastouch017 6 월 전
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

FDA clearance triggers a $30 million milestone payment from Gilead
👍️0
Monksdream Monksdream 6 월 전
GILD under $100
👍️0
TechandBio TechandBio 6 월 전
Target is $100-$120 by Q2 2025

$GILD
👍️0
TechandBio TechandBio 6 월 전
HIV Prevention CURE Shot 2x a year

Great growing oncology pipeline!

my $80 vertical Calls from last week are looking golden!

$GILD
👍️0
north40000 north40000 7 월 전
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
👍️0
north40000 north40000 7 월 전
How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
👍️0
jondoeuk jondoeuk 8 월 전
There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
👍️0
jondoeuk jondoeuk 8 월 전
A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
👍️0
jondoeuk jondoeuk 8 월 전
They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
👍️0
jondoeuk jondoeuk 8 월 전
''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
👍️0
jondoeuk jondoeuk 8 월 전
The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
👍️0
jondoeuk jondoeuk 9 월 전
The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
👍️0
jondoeuk jondoeuk 10 월 전
IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
👍️0
jondoeuk jondoeuk 10 월 전
Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
👍️0
jondoeuk jondoeuk 10 월 전
Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
👍️0
jondoeuk jondoeuk 10 월 전
I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
👍️0
jondoeuk jondoeuk 10 월 전
Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
👍️0
Monksdream Monksdream 12 월 전
GILD new 52 week high
👍️0
jondoeuk jondoeuk 1 년 전
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
👍️0
jondoeuk jondoeuk 1 년 전
Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them
👍️0
jondoeuk jondoeuk 1 년 전
The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
👍️0
Greedy G Greedy G 1 년 전
~bought 9/22 $80 calls .08c
👍️0
jondoeuk jondoeuk 2 년 전
Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
👍️0
DewDiligence DewDiligence 2 년 전
Why is an oral prodrug of Remdesivir anything to get excited about?
👍️0
jondoeuk jondoeuk 2 년 전
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
👍️0
jondoeuk jondoeuk 2 년 전
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
👍️0
fink fink 2 년 전
Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1
👍️0
fink fink 2 년 전
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
👍️0
PennyPusher786 PennyPusher786 2 년 전
It's at a 3 year high
👍️0
fung_derf fung_derf 2 년 전
Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
👍️0
fink fink 2 년 전
Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.
👍️0
jondoeuk jondoeuk 2 년 전
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
👍️0
Zeppo Zeppo 3 년 전
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
👍️0
DewDiligence DewDiligence 3 년 전
GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.
👍️0
mick mick 3 년 전
Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote
👍️0
jondoeuk jondoeuk 3 년 전
ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




👍️0

최근 히스토리

NASDAQ
GILD
Gilead Sciences
BIT
1BOSS
Hugo Boss
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유